Cargando…
Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
PURPOSE: Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that plays a major role in brain cholesterol homeostasis by converting cholesterol into 24S-hydroxycholesterol. The selective CH24H inhibitor soticlestat (TAK-935) is being pursued as a drug for treatment of seizures in developme...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921165/ https://www.ncbi.nlm.nih.gov/pubmed/34651220 http://dx.doi.org/10.1007/s00259-021-05565-z |
_version_ | 1784669278385995776 |
---|---|
author | Koike, Tatsuki Constantinescu, Cristian C. Ikeda, Shuhei Nishi, Toshiya Sunahara, Eiji Miyamoto, Maki Cole, Patricia Barret, Olivier Alagille, David Papin, Caroline Morley, Thomas Fowles, Krista Seibyl, John Tamagnan, Gilles Kuroita, Takanobu |
author_facet | Koike, Tatsuki Constantinescu, Cristian C. Ikeda, Shuhei Nishi, Toshiya Sunahara, Eiji Miyamoto, Maki Cole, Patricia Barret, Olivier Alagille, David Papin, Caroline Morley, Thomas Fowles, Krista Seibyl, John Tamagnan, Gilles Kuroita, Takanobu |
author_sort | Koike, Tatsuki |
collection | PubMed |
description | PURPOSE: Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that plays a major role in brain cholesterol homeostasis by converting cholesterol into 24S-hydroxycholesterol. The selective CH24H inhibitor soticlestat (TAK-935) is being pursued as a drug for treatment of seizures in developmental and epileptic encephalopathies. Herein, we describe the successful discovery and the preclinical validation of the novel radiolabeled CH24H ligand (3-[(18)F]fluoroazetidin-1-yl){1-[4-(4-fluorophenyl)pyrimidin-5-yl]piperidin-4-yl}methanone ([(18)F]T-008) and its tritiated analog, [(3)H]T-008. METHODS: In vitro autoradiography (ARG) studies in the CH24H wild-type (WT) and knockout (KO) mouse brain sections were conducted using [(3)H]T-008. PET imaging was conducted in two adult rhesus macaques using [(18)F]T-008. Each macaque received two test–retest baseline scans and a series of two blocking doses of soticlestat administered prior to [(18)F]T-008 to determine the CH24H enzyme occupancy. PET data were analyzed with Logan graphical analysis using plasma input. A Lassen plot was applied to estimate CH24H enzyme occupancy by soticlestat. RESULTS: In ARG studies, binding of [(3)H]T-008 was specific to CH24H in the mouse brain sections, which was not observed in CH24H KO or in wild-type mice after pretreatment with soticlestat. In rhesus PET studies, the rank order of [(18)F]T-008 uptake was striatum > cortical regions > cerebellum, which was consistent with CH24H distribution in the brain. Pre-blocking with soticlestat reduced the maximum uptake and increased the washout in all brain regions in a dose-dependent manner. Calculated global occupancy values for soticlestat at a dose of 0.89 mg/kg were 97–98%, indicating maximum occupancy. CONCLUSION: The preclinical in vitro and in vivo evaluation of labeled T-008 demonstrates that [(18)F]T-008 is suitable for imaging CH24H in the brain and warrants further studies in humans. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05565-z. |
format | Online Article Text |
id | pubmed-8921165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89211652022-03-17 Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase Koike, Tatsuki Constantinescu, Cristian C. Ikeda, Shuhei Nishi, Toshiya Sunahara, Eiji Miyamoto, Maki Cole, Patricia Barret, Olivier Alagille, David Papin, Caroline Morley, Thomas Fowles, Krista Seibyl, John Tamagnan, Gilles Kuroita, Takanobu Eur J Nucl Med Mol Imaging Original Article PURPOSE: Cholesterol 24-hydroxylase (CH24H) is a brain-specific enzyme that plays a major role in brain cholesterol homeostasis by converting cholesterol into 24S-hydroxycholesterol. The selective CH24H inhibitor soticlestat (TAK-935) is being pursued as a drug for treatment of seizures in developmental and epileptic encephalopathies. Herein, we describe the successful discovery and the preclinical validation of the novel radiolabeled CH24H ligand (3-[(18)F]fluoroazetidin-1-yl){1-[4-(4-fluorophenyl)pyrimidin-5-yl]piperidin-4-yl}methanone ([(18)F]T-008) and its tritiated analog, [(3)H]T-008. METHODS: In vitro autoradiography (ARG) studies in the CH24H wild-type (WT) and knockout (KO) mouse brain sections were conducted using [(3)H]T-008. PET imaging was conducted in two adult rhesus macaques using [(18)F]T-008. Each macaque received two test–retest baseline scans and a series of two blocking doses of soticlestat administered prior to [(18)F]T-008 to determine the CH24H enzyme occupancy. PET data were analyzed with Logan graphical analysis using plasma input. A Lassen plot was applied to estimate CH24H enzyme occupancy by soticlestat. RESULTS: In ARG studies, binding of [(3)H]T-008 was specific to CH24H in the mouse brain sections, which was not observed in CH24H KO or in wild-type mice after pretreatment with soticlestat. In rhesus PET studies, the rank order of [(18)F]T-008 uptake was striatum > cortical regions > cerebellum, which was consistent with CH24H distribution in the brain. Pre-blocking with soticlestat reduced the maximum uptake and increased the washout in all brain regions in a dose-dependent manner. Calculated global occupancy values for soticlestat at a dose of 0.89 mg/kg were 97–98%, indicating maximum occupancy. CONCLUSION: The preclinical in vitro and in vivo evaluation of labeled T-008 demonstrates that [(18)F]T-008 is suitable for imaging CH24H in the brain and warrants further studies in humans. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05565-z. Springer Berlin Heidelberg 2021-10-15 2022 /pmc/articles/PMC8921165/ /pubmed/34651220 http://dx.doi.org/10.1007/s00259-021-05565-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Koike, Tatsuki Constantinescu, Cristian C. Ikeda, Shuhei Nishi, Toshiya Sunahara, Eiji Miyamoto, Maki Cole, Patricia Barret, Olivier Alagille, David Papin, Caroline Morley, Thomas Fowles, Krista Seibyl, John Tamagnan, Gilles Kuroita, Takanobu Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase |
title | Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase |
title_full | Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase |
title_fullStr | Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase |
title_full_unstemmed | Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase |
title_short | Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase |
title_sort | preclinical characterization of [(18)f]t-008, a novel pet imaging radioligand for cholesterol 24-hydroxylase |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921165/ https://www.ncbi.nlm.nih.gov/pubmed/34651220 http://dx.doi.org/10.1007/s00259-021-05565-z |
work_keys_str_mv | AT koiketatsuki preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT constantinescucristianc preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT ikedashuhei preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT nishitoshiya preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT sunaharaeiji preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT miyamotomaki preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT colepatricia preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT barretolivier preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT alagilledavid preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT papincaroline preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT morleythomas preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT fowleskrista preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT seibyljohn preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT tamagnangilles preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase AT kuroitatakanobu preclinicalcharacterizationof18ft008anovelpetimagingradioligandforcholesterol24hydroxylase |